Table 2.
Predicted known therapeutics
| PH | Target | *Drug name | Status | Action | *Database |
|---|---|---|---|---|---|
| T1D | PPARG | Rosiglitazone | Approved | Agonist | TTD |
| DGKA | Vitamin E | Approved | Unknown | DrugBank | |
| T2D | CTSD | Insulin Regular | Approved | Unknown | DrugBank |
| PPARA | Aleglitazar | Phase III | Agonist | TTD | |
| NR3C1 | ISIS-GCCR | Preclinical | Antisense | TTD | |
| TCF7L2 | Repaglinide | Unknown | Unknown | PharmGKB | |
| PPARD | Bezafibrate | Approved | Agonist | DrugBank | |
| RB1 | Insulin, porcine | Approved | Unknown | DrugBank | |
| HSD11B1 | INCB13739 | Phase IIa | Inhibitor | TTD | |
| RA | TNF | Infliximab | Approved | Inhibitor | DrugBank |
| ITGA4 | CDP323 | Phase II | Antagonist | TTD | |
| JAK2 | INCB18424 | Phase III | Inhibitor | TTD | |
| IL15 | AMG-714 | Discontinued in phase I | Inhibitor | TTD | |
| CCL2 | MCP-1 | Preclinical | Inhibitor | TTD | |
| PRKCA | Vitamin E | Approved | Unknown | DrugBank | |
| HT | DRD1 | Fenoldopam | Approved | Agonist | TTD |
| AGTR1 | Valsartan | Approved | Antagonist | TTD | |
| CNR1 | AZD1175 | Discontinued in phase I | Antagonist | TTD | |
| AGT | Benazepril | Unknown | Unknown | PharmGKB | |
| GUCY1A2 | Isosorbide Mononitrate | Approved | Inducer | DrugBank | |
| BD | SLC6A2 | Imipramine | Approved | Inhibitor | DrugBank |
| AGTR1 | Valsartan | Approved | Antagonist | DrugBank | |
| CAD | MYC | AVI4126 | Phase I/II | Antisense | TTD |
| PLG | Urokinase | Approved | Activator | DrugBank | |
| NOS3 | ACCLAIM | Phase III | Stimulator | TTD | |
Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; BD - Bipolar Disorder; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
Therapeutic targets with predicted known therapeutics for phenotypes of interest.
(* Drugs mentioned in the table are only examples as one target may have multiple drugs);
(* Drug databases in the table are only examples as one drug-target association may be present in more than one database).